For example, F-circEA, but not its host linear mRNA, could be detected in EML4–ALK+ lung cancer plasma; thus, circulating F-circEA would be a novel biomarker to detect EML4–ALK fusion and to determine an effective treatment for EML4-ALK+ patients [54]. The gene discussed is EML4; the disease is lung cancer.